Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07567846
PHASE1/PHASE2

A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer

Sponsor: Genentech, Inc.

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-1261 in participants with advanced or metastatic prostate cancer. It's also to identify a recommended dose(s) and regimen for GDC-1261 for subsequent studies.

Official title: A Phase I/II Dose-escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Patients With Advanced or Metastatic Prostate Cancer

Key Details

Gender

MALE

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

260

Start Date

2026-04-29

Completion Date

2027-12-30

Last Updated

2026-06-11

Healthy Volunteers

No

Interventions

DRUG

GDC-1261

Participants will receive GDC-1261 as per the schedule described in the protocol.

Locations (2)

Honor Health Research Institute

Scottsdale, Arizona, United States

Sarah Cannon Research Institute

Nashville, Tennessee, United States